Previously Treated CLL/SLL

VENCLEXTA + RITUXIMAB
OFFERS A CHANCE
FOR A TREATMENT-FREE
PERIOD AFTER ~24 MONTHS

Actor portrayal.

VENCLEXTA + rituximab was studied in a clinical trial

A significantly lowered chance of disease progression or death

In a clinical study of 389 people who have been previously treated for CLL, VENCLEXTA was studied with an antibody treatment called rituximab. This regimen is not a chemotherapy and was studied against a commonly used chemotherapy-containing regimen. Approximately half of the patients (194) received VENCLEXTA + rituximab and the other 195 patients received the chemotherapy-containing regimen (bendamustine and rituximab). The VENCLEXTA-containing regimen was proven to be more effective than the chemotherapy-containing regimen.

The chance of disease worsening or death was 81% lower with the VENCLEXTA regimen (194 people) than with the chemotherapy-containing regimen (195 people). Doctors generally call this progression-free survival or PFS.

Please take note that the median PFS was not reached for the VENCLEXTA and rituximab arm of the study. This was based on median follow-up of 23.4 months. A definition of median is the “middle” value of a sorted list of numbers. The study was not yet able to determine the median* time that patients lived without their disease worsening because more than half of patients were both alive and had not yet experienced a worsening of their disease.

VENCLEXTA can cause serious side effects, including tumor lysis syndrome, low white blood cell count, and infections. These are not all of the possible side effects of VENCLEXTA. Talk to your healthcare provider for more information about the risks and side effects of VENCLEXTA. Please click here for additional Important Safety Information.

*Please note that the median PFS was not reached for the VENCLEXTA and rituximab arm of the study but the median PFS for the bendamustine and rituximab arm was 18.1 months. A definition of median is the "middle" value of a sorted list of numbers.

Pill bottle with question mark

Download helpful questions to discuss with your doctor about VENCLEXTA treatment

Individual results may vary

Individual results may vary

  

Remission defined

Remission means that the signs of cancer have lessened or are no longer detectable, although cancer may still be in the body.

Complete remission means that all signs and symptoms of cancer have disappeared for a period of time, but cancer may still be in the body.

Complete remission with incomplete marrow recovery means that most signs and symptoms of cancer disappeared for a period of time except that platelet, white blood cell, or red blood cell counts remained low.

Partial remission means that there are still signs of cancer, but your treatment regimen is working because the number of cancer cells in your body has greatly decreased. Nodular partial remission (nPR) is a type of partial remission, but bone marrow biopsies show rare nodules.

Remission with the confidence to stop treatment

The remission rates people in the clinical trial experienced are:

  • 92% of people achieved some level of remission (179 of 194 people) with VENCLEXTA + rituximab compared to 72% (141 of 195 people) of people with bendamustine and rituximab
  • 8% of people achieved complete remission or complete remission without incomplete marrow recovery (16 of 194 people) with VENCLEXTA + rituximab compared to 4% (7 of 195 people) with bendamustine and rituximab
  • 82% of people achieved a partial remission (160 of 194 people) with VENCLEXTA + rituximab compared to 68% (133 of 195 people) of people with bendamustine and rituximab
  • 2% of people achieved a nodular partial remission (3 of 194) with VENCLEXTA + rituximab compared to 1% (1 of 195) of people with bendamustine and rituximab

 

Actor portrayal.

You can be free of detectable disease in your blood

After completing VENCLEXTA treatment, some people had such a low level of CLL cells (fewer than 1 cancer cell per 10,000 white blood cells) that the cells were not detectable using sensitive clinical tests. This is known as undetectable minimal residual disease (MRD) or MRD negativity.

  • 53% of people (103 of 194) had no detectable cancer in their blood 3 months after treatment with VENCLEXTA + rituximab compared to 12% of people (23 of 195) had no detectable cancer in their blood 3 months after treatment with bendamustine and rituximab

Please take note that undetectable MRD or MRD negativity does not necessarily equal successful treatment due to limitations with MRD testing. For instance, it is possible for patients to have a partial response to treatment while still testing as MRD negative and patients can have a complete response and be MRD positive.

Actor portrayal.

PATIENT BROCHURE

Get more information about treatment with VENCLEXTA

Actor portrayal.

Learn more about how VENCLEXTA can help